A proposal for improvement of the first-line treatment of advanced diabetic retinopathy
Article Sidebar
Main Article Content
Abstract
Diabetic retinopathy (DR) can be resulted from high blood glucose levels that may damage the retinal pigment epithelium, located between the vascular choroids and the neurosensory retina, which functions as a barrier. The first-line treatment of DR comprises an anti-vascular endothelial growth factor (anti-VEGF) compound such as Avastin (bevacizumab), Lucentis (ranibizumab) and Eylea (aflibercept). Some patients suffering from static condition of advanced DR need a treatment that will lead to improvement of the DR condition, e.g., reduction of abnormal blood vessels on the optic disc and preventing further ischemic optic neuropathy. Thus, a combined simultaneous treatment of an anti-VEGF compound such as Avastin, or a biosimilar version, and oral administration of fucoxanthin that has a protective effect on the retina, optionally together with vitamin A, is proposed for treating advanced DR.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
[1] Munz I.V., Direev A.O., Gusarevitch O.G., Scherbakova L.V., Mazdorova E.V., Malyutina S.K., "Prevalence of ophthalmic diseases in the population older than 50 years". Vestn. Oftalmol. 2020,136:106–115.
[2] Maeda H., Hosokawa M., Sashima T., Funayama K., Miyashita K., "Fucoxanthin from edible seaweed Undaria Pinnatifida shows anti-obesity effect through UCP1 expression in white adipose tissues". Biochem. Biophys. Res. Commun., 2005, 332(2), 392-397.
[3] Maeda H., Hosokawa M., Sashima T., Takahashi N., Kawada T., and Miyashita K., "Fucoxanthin and its metabolite, fucoxanthinol, suppress adipocite differentiation in 3T3-L1 cells". J. Mol. Med., 2006, 18(1), 147-152.
[4] Asai A., Sugawara T., Ono H., Nagao A., "Biotransformation of fucoxanthinol into amarouciaxanthin A in mice and HepG2 cells, formation and cytotoxicity of fucoxanthin metabolites". Drug Metabolism and Disposition, 2004, vol. 32, no. 2, pp. 205–211.
[5] Hashimoto T., Ozaki Y., Tamiato M., Das S.K., Mizuno M., Yoshimura K., Maoka T., Kanazawa K., "The distribution and accumulation of fucoxanthin and its metabolites after oral administration in mice". British Journal of Nutrition, 2009, vol. 102, no. 2, pp. 242–248.
[6] Komba S., Kotake-Nara E., Tsuzuki W., "Degradation of fucoxanthin to elucidate the relationship between the fucoxanthin molecular structure and its antiproliferative effect on Caco-2 cells". Mar. Marine Drugs, 2018, 16(8), 275.
[7] Chiang Y.F., Chen H.Y., Chang Y.J., Shih Y.H., Shieh T.M., Wang K.L., Hsia S.M., "Protective effects of fucoxanthin on high-glucose and 4-hydroxynonenal-induced injury in human retinal pigment epithelial cells". Antioxidants (Basel), 2020; 9(12):1176.